All Photos(2)



Anti-phospho-AKT1 (pSer473) antibody produced in rabbit

affinity isolated antibody

Anti-v-akt murine thymoma viral oncogene homolog 1 antibody produced in rabbit, Anti-PKB antibody produced in rabbit, Anti-AKT antibody produced in rabbit, Anti-MGC99656 antibody produced in rabbit, Anti-PKB-ALPHA antibody produced in rabbit

biological source


Quality Level



antibody form

affinity isolated antibody

antibody product type

primary antibodies




buffered aqueous solution

mol wt

~60 kDa

species reactivity

mouse, human, rat


1 mg/mL


immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:100
western blot: 1:500-1:1000



immunogen sequence


NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.


Gene Information

human ... AKT1(207)


Peptide sequence around phosphorylation site of serine 473 (Q-F-S(p)-Y-S), according to the protein AKT1.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Target description

General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI3K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase.

Physical form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

12 - Non Combustible Liquids



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

Dongqing Zheng et al.
Journal of cell science, 133(7) (2020-02-26)
Oncogenes can create metabolic vulnerabilities in cancer cells. We tested how AKT (herein referring to AKT1) and MYC affect the ability of cells to shift between respiration and glycolysis. Using immortalized mammary epithelial cells, we discovered that constitutively active AKT
Yingpinyapat Kittirat et al.
Oncology letters, 15(1), 347-353 (2018-02-02)
The protein 14-3-3ζ contributes important regulatory functions in several cellular processes via binding to phosphorylated serine/threonine residues, which promotes cell cycle progression, cell proliferation and anti-apoptosis in multiple types of cancer. The aim of the present study was to investigate
Dong Liang et al.
Investigational new drugs, 38(5), 1218-1226 (2019-12-12)
The PI3K pathway is aberrantly activated in many cancers and plays a critical role in tumour cell proliferation and survival, making it a rational therapeutic target. In the present study, the effects and the underlying mechanism of a new PI3K
Yoki Nakamura et al.
Journal of neurochemistry, 131(6), 755-766 (2014-09-02)
Intraplantar injection of 0.4% formalin into the rat hind paw leads to a biphasic nociceptive response; an 'acute' phase (0-15 min) and 'tonic' phase (16-120 min), which is accompanied by significant phosphorylation of extracellular signal-regulated kinase (ERK)1/2 in the contralateral
Amita Vaidya et al.
Cells, 9(8) (2020-08-07)
Breast tumor heterogeneity is a major impediment to oncotherapy. Cancer cells undergo rapid clonal evolution, thereby acquiring significant growth and invasive advantages. The absence of specific markers of these high-risk populations precludes efficient therapeutic and diagnostic management of the disease.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service